Scilex Holding Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Jaisim Shah

Chief executive officer

US$7.4m

Total compensation

CEO salary percentage	12.4%
CEO tenure	2yrs
CEO ownership	0.2%
Management average tenure	2yrs
Board average tenure	1.2yrs

Recent management updates

Recent updates

Analysts Just Shaved Their Scilex Holding Company (NASDAQ:SCLX) Forecasts Dramatically

Jun 14

It's Down 33% But Scilex Holding Company (NASDAQ:SCLX) Could Be Riskier Than It Looks

Apr 24

Scilex Holding Company's (NASDAQ:SCLX) 35% Price Boost Is Out Of Tune With Revenues

Feb 28

Risks To Shareholder Returns Are Elevated At These Prices For Scilex Holding Company (NASDAQ:SCLX)

Dec 21

Scilex Holding Company's (NASDAQ:SCLX) 56% Dip In Price Shows Sentiment Is Matching Earnings

May 06

CEO Compensation Analysis

How has Jaisim Shah's remuneration changed compared to Scilex Holding's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	n/a	n/a	-US$172m
Mar 31 2024	n/a	n/a	-US$161m
Dec 31 2023	US$7m	US$917k	-US$167m
Sep 30 2023	n/a	n/a	-US$163m
Jun 30 2023	n/a	n/a	-US$54m
Mar 31 2023	n/a	n/a	-US$45m
Dec 31 2022	US$786k	US$773k	-US$23m
Sep 30 2022	n/a	n/a	-US$47m
Jun 30 2022	n/a	n/a	-US$81m
Mar 31 2022	n/a	n/a	-US$78m
Dec 31 2021	US$881k	US$579k	-US$88m

Compensation vs Market: Jaisim's total compensation ($USD7.37M) is above average for companies of similar size in the US market ($USD651.40K).

Compensation vs Earnings: Jaisim's compensation has increased whilst the company is unprofitable.

CEO

Jaisim Shah (64 yo)

2yrs

Tenure

US$7,373,977

Compensation

Mr. Jaisim Shah serves as Chief Executive Officer and President of SCILEX Pharmaceuticals, Inc. since March 2019. He serves as Chief Executive Officer, President and Director of Scilex Holding Company sinc...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Henry Ji	Executive Chairman	1.2yrs	US$33.92m	0.47% $ 377.0k
Jaisim Shah	President	2yrs	US$7.37m	0.20% $ 161.8k
Stephen Ma	Senior VP	1.2yrs	US$2.14m	0.017% $ 13.9k
Suketu Desai	CTO & Senior VP	2yrs	no data	no data
Steven Lincoln	General Counsel & Chief Compliance Officer	no data	no data	no data
Sumant Rajendran	Executive Director of Marketing	no data	no data	no data
Mike Ciaffi	National Sales Director	no data	no data	no data
Suresh Khemani	Senior VP & Chief Commercial Officer	2yrs	US$456.82k	no data
Dmitri Lissin	Senior VP & Chief Medical Officer	2yrs	US$528.83k	no data
Gigi DeGuzman	Senior Executive Director & Chief of Staff	less than a year	no data	no data
Elaine Chan	Executive Director & Head of Medical Affairs	2.8yrs	no data	no data

2.0yrs

Average Tenure

62yo

Average Age

Experienced Management: SCLX's management team is considered experienced (2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Henry Ji	Executive Chairman	1.2yrs	US$33.92m	0.47% $ 377.0k
Jaisim Shah	President	2yrs	US$7.37m	0.20% $ 161.8k
David Lemus	Independent Director	2yrs	US$750.00k	0.0015% $ 1.2k
Yue Wu	Independent Director	1.2yrs	US$285.67k	0.019% $ 15.2k
Dorman Followwill	Independent Director	2yrs	US$750.00k	0.0018% $ 1.4k
Jay Chun	Independent Director	1.2yrs	US$277.43k	0.085% $ 68.6k
Annu Navani	Director	less than a year	no data	no data

1.2yrs

Average Tenure

60.5yo

Average Age

Experienced Board: SCLX's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.

Scilex Holding Management

Management criteria checks 1/4

Key information

Recent management updates

Scilex Holding Company Appoints Annu Navani as Board of Directors

President recently bought US$122k worth of stock

Scilex Holding Company, Annual General Meeting, Apr 05, 2024

High number of new and inexperienced directors

Scilex Holding Company Announces Management Changes

Scilex Holding Company Announces Management Changes

Recent updates

Scilex Holding Company announced delayed 10-Q filing

New minor risk - Shareholder dilution

Scilex Holding Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Consensus EPS estimates upgraded to US$0.74 loss, revenue downgraded

Price target increased by 43% to US$7.63

Scilex Holding Company has completed a Follow-on Equity Offering in the amount of $50 million.

Scilex Holding Company Provides Preliminary Unaudited Sales Guidance for the Quarter Ended September 30, 2024

Scilex Holding Company has filed a Follow-on Equity Offering.

Scilex Holding Company Announces FDA Final Approval to Precision Dosing for GLOPERBA Label

Consensus EPS estimates fall by 62%, revenue upgraded

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Scilex Holding Company Provides Preliminary Unaudited Sales Guidance for the Month Ended July 31, 2024

Scilex Holding Company Appoints Annu Navani as Board of Directors

Scilex Holding Company Announces Publication in Pain Journal Regarding Phase 3 Results of the Pivotal Registration Trial of Sp-102 (Semdexa™) in Lumbosacral Radicular Pain (Sciatica)

Analysts Just Shaved Their Scilex Holding Company (NASDAQ:SCLX) Forecasts Dramatically

Consensus revenue estimates fall by 19%

Scilex Holding Company Announces FDA Approval of Commercial Manufacturing of Gloperba

President recently bought US$122k worth of stock

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Scilex Holding Company has completed a Follow-on Equity Offering in the amount of $15 million.

It's Down 33% But Scilex Holding Company (NASDAQ:SCLX) Could Be Riskier Than It Looks

Scilex Holding Company has filed a Follow-on Equity Offering.

New minor risk - Market cap size

Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba®? Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment Is Needed

Scilex Holding Company and Scilex Pharmaceuticals, Inc. Announces Settlement Agreement with Takeda Pharmaceuticals Company Ltd and Takeda Pharmaceuticals U.S.A., Inc

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Scilex Holding Company, Annual General Meeting, Apr 05, 2024

Scilex Holding Company has filed a Follow-on Equity Offering.

Scilex Holding Company's (NASDAQ:SCLX) 35% Price Boost Is Out Of Tune With Revenues

Scilex Holding Company Provides Sales Guidance for the Fiscal Year Ended December 31, 2023

Scilex Holding Company Announces Filing of New Drug Submission to Health Canada's Pharmaceutical Drugs Director, Bureau of Cardiology, Allergy and Neurological Sciences for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada

Scilex Holding Company has filed a Follow-on Equity Offering in the amount of $170 million.

Scilex Holding Company has filed a Follow-on Equity Offering in the amount of $170 million.

Risks To Shareholder Returns Are Elevated At These Prices For Scilex Holding Company (NASDAQ:SCLX)

High number of new and inexperienced directors

Scilex Holding Company Announces Results from Market Research with Rheumatologists Reveal A High Degree of Interest in Gloperba as Liquid Colchicine Formulation Designed for Precision Dosing

Scilex Holding Company Announces ZTlido Will Be Added as a Preferred Agent to the Medicaid Preferred Drug List (PDL) in Two New States: One Midwestern and One Southern State

Scilex Holding Company Announces the Addition of Ztlido (Lidocaine Topical System) as A Preferred Agent to the Medicaid Preferred Drug List (Pdl) of the State of the State of Tennessee

Scilex Holding Company Announces Successful Fda Audit of Enhanced Ztlido®? Manufacturing Facility in Japan

Scilex Holding Company Announces Completion of Commercial Manufacturing of Gloperba

Scilex Holding Company Announces Completion of Commercial Manufacturing of Gloperba

Scilex Holding Company Announces Market Research Results with Neurologists, Headache Specialists, and Primary Care Physicians Demonstrating Potential High Unmet Needs in Treating Acute Migraine Targeted by ELYXYB

Scilex Holding Company Announces Production Increase, Product Availability

Scilex Holding Company Announces Positive Type C Meeting with the Fda and Reaches Agreement on Path Forward to File an Nda for Sp-102 in Lumbosacral Radicular Pain (Sciatica)

Scilex Holding Company Announces New Data From Deeper Skin Penetration Studies to Support SP-103 (lidocaine topical system) 5.4%, a Triple Strength Formulation of ZTlido®, in Treatment of Musculoskeletal Pain Disorders

Scilex Holding Company Announces Management Changes

Scilex Holding Company Announces Management Changes

Scilex Holding Company Announces the Completion of its SP-103 Phase 2

Scilex Holding Company Presents Oral and Poster Presentations on ZTlido (lidocaine Topical System) at the 2023 Annual PAINWeek Conference Held in Las Vegas, NV

Scilex Holding Company Provides Sales Guidance for the Month and Year to Date Ended August 31, 2023

Scilex Holding Company Announces Retirement of Jaisim Shah as Chief Executive Officer

Second quarter 2023 earnings released: US$0.19 loss per share (vs US$0.09 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.22 loss per share (vs US$0.046 loss in 1Q 2022)

Scilex Holding Company's (NASDAQ:SCLX) 56% Dip In Price Shows Sentiment Is Matching Earnings

Scilex Holding Company Announces Complete Enrollment of A Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 (Lidocaine Topical System) 5.4%, Triple Strength Formulation of Ztlido, for the Treatment of Acute Low Back Pain

Full year 2022 earnings released: US$0.17 loss per share (vs US$0.45 loss in FY 2021)

Scilex Holding Company Acquires Rights to FDA-Approved ELYXYB in the U.S. and Canada for the Acute Treatment of Migraine

Scilex Holding Company, Annual General Meeting, Apr 06, 2023

High number of new and inexperienced directors

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age